⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 13, 2021CancerOpen Access

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Kunhwa Kim Abhishek Maiti Sanam Loghavi Rasoul Pourebrahim Tapan M. Kadia Caitlin R. Rausch Ken Furudate Naval Daver Yesid Alvarado Maro Ohanian Koji Sasaki Nicholas J. Short Koichi Takahashi Musa Yılmaz Guilin Tang Farhad Ravandi Hagop M. Kantarjian Courtney D. DiNardo Marina Konopleva

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Patients with TP53mut AML have lower response rates and shorter survival with DEC10-VEN.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kim et al. (2021) studied this question.

synapsesocial.com/papers/69d80a6bfc5937d393ae2bc8 https://doi.org/10.1002/cncr.33689

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical UsePrognostic Study · 2009 · 2,194 citations
2Genomic Classification and Prognosis in Acute Myeloid LeukemiaPrognostic Study · 2016 · 4,338 citations
3<i>TP53</i> mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomesOriginal Research · 2016 · 261 citations
4Clinical response and <i>miR-29b</i> predictive significance in older AML patients treated with a 10-day schedule of decitabineCohort Study · 2010 · 450 citations
5Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapyRetrospective Study · 2013 · 51 citations

More related papers

<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes2016
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia2020
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells2019

More from Cancer

Risk factors and outcome of children and young adults with initially unresected nonrhabdomyosarcoma soft tissue sarcoma: An analysis from the International Soft Tissue Sarcoma ConsortiumThu,
Cancer risks associated with BRCA1 and BRCA2 : Overview and managementWed,